These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 9800891)

  • 1. Use of novel urodynamic parameters, detrusor contraction duration and detrusor contraction index, in men with lower urinary tract symptoms.
    Turner CD; Kuznetsov D; Contreras BA; Gerber GS
    Tech Urol; 1998 Sep; 4(3):136-40. PubMed ID: 9800891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Contreras BA; Rukstalis DB
    Tech Urol; 1997; 3(3):164-7. PubMed ID: 9422449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Kim JH; Contreras BA; Steinberg GD; Rukstalis DB
    Urology; 1996 Jun; 47(6):840-4. PubMed ID: 8677574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months.
    Gerber GS; Contreras BA; Zagaja GP; Kim JH; Steinberg GD; Rukstalis DB
    Urology; 1997 Aug; 50(2):229-33. PubMed ID: 9255293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detrusor contraction duration as a urodynamic parameter of bladder outlet obstruction for evaluating men with lower urinary tract symptoms.
    Ameda K; Steele GS; Sullivan MP; Stember D; Yalla SV
    J Urol; 1998 Aug; 160(2):482-6. PubMed ID: 9679903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detrusor contraction duration may predict response to alpha-blocker therapy for lower urinary tract symptoms.
    Kaplan SA; Stifelman M; Avillo C; Reis RB; Te AE
    Eur Urol; 2000 Mar; 37(3):314-7. PubMed ID: 10720858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Urodynamic criteria of predicting efficacy of therapy with alpha1-adrenergic blockaders in patients with benign prostatic hyperplasia].
    Sivkov AV; Egorov AA; Romikh VV; Surikov VN
    Urologiia; 2002; (5 Suppl):13-22. PubMed ID: 12518669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of doxazosin efficacy in the treatment of the benign prostatic enlargement].
    Aganović D; Aganović K; Prcić A
    Med Arh; 2004; 58(3):153-6. PubMed ID: 15484855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voiding dysfunction following transurethral resection of the prostate: symptoms and urodynamic findings.
    Nitti VW; Kim Y; Combs AJ
    J Urol; 1997 Feb; 157(2):600-3. PubMed ID: 8996367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant correlation of the American Urological Association symptom score and a novel urodynamic parameter: detrusor contraction duration.
    Kaplan SA; Reis RB
    J Urol; 1996 Nov; 156(5):1668-72. PubMed ID: 8863567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
    Lee JY; Kim HW; Lee SJ; Koh JS; Suh HJ; Chancellor MB
    BJU Int; 2004 Oct; 94(6):817-20. PubMed ID: 15476515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM; Klarskov P
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association among the symptoms, quality of life and urodynamic parameters in patients with improved lower urinary tract symptoms following a transurethral resection of the prostate.
    Seki N; Yunoki T; Tomoda T; Takei M; Yamaguchi A; Naito S
    Neurourol Urodyn; 2008; 27(3):222-5. PubMed ID: 17580358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
    Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized trial comparing transurethral prostatic resection and clean intermittent self-catheterization in men with chronic urinary retention.
    Ghalayini IF; Al-Ghazo MA; Pickard RS
    BJU Int; 2005 Jul; 96(1):93-7. PubMed ID: 15963128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The resolution of detrusor over activity after medical and surgical treatment in patients with bladder outlet obstruction.
    Sriplakich S; Promwatcharanon K
    J Med Assoc Thai; 2007 Nov; 90(11):2326-31. PubMed ID: 18181315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
    Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomón Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):840-5. PubMed ID: 9463281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
    Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
    Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.